Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.60 |
| ▸ | RET | P07949 | 8/20 | 0.55 |
| ▸ | KIF5B | P33176 | 4/20 | 0.55 |
| ▸ | ILK | Q13418 | 2/20 | 0.54 |
| ▸ | KDR | P35968 | 5/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.52 |
| ▸ | GAK | O14976 | 2/20 | 0.52 |
| ▸ | PLK4 | O00444 | 1/20 | 0.52 |
| ▸ | CIT | O14578 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 1/20 | 0.52 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | BUB1 | O43683 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.52 |
| ▸ | STK17B | O94768 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3172507 | 0.90 | EGFR (0.67) | EGFRRETKIF5BILKKDR | |
| SCHEMBL4127912 | 0.89 | FBP1 (0.64) | EGFRRETKIF5BILKKDR | |
| Hydrochloric Acid SCHEMBL1507513 | 0.88 | EGFR (0.63) | EGFRRETKIF5BILKKDR | |
| SCHEMBL1507462 | 0.86 | RET (0.70) | EGFRRETKIF5BILKKDR | |
| Hydrochloric Acid SCHEMBL8681050 | 0.82 | EGFR (0.57) | EGFRRETKIF5BILKKDR | |
| SCHEMBL16760388 | 0.82 | RET (0.84) | EGFRRETKIF5BKDRAURKB | |
| SCHEMBL4736845 | 0.80 | EGFR (0.66) | EGFRRETILKKDRERBB2 | |
| Hydrochloric Acid SCHEMBL4877663 | 0.79 | EGFR (0.66) | EGFRRETILKKDRERBB2 | |
| SCHEMBL1507594 | 0.78 | EGFR (0.89) | EGFRRETILKKDRERBB2 | |
| SCHEMBL27719215 | 0.78 | FBP1 (0.60) | EGFRRETKIF5BILKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1859793-A1 | NOVEL COMBINATIONAL USE OF SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EGFR, KIT, ERBB2 | EGFR 1/4885RET 15/4885KIF5B 1740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.